A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY Study)

Protocol No
PULM-BOEHRINGER-AIRTIVITY
Staff Member
Julie Biller
Phase
III
Summary

This project is being done to compare the study drug called BI 1291583 to a placebo to see if it may help people with bronchiectasis.

Objective
The AIRTIVITY Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Status
OPEN TO ACCRUAL